Asian press release distribution

Press Releases for Monday, October 5, 2020

China Biotech Services (8037.HK) and National Institute for Viral Disease Control and Prevention (NIVDC) to develop Genetically Engineered Recombinant Vaccine for COVID-19 21:30 HKT/SGT

Roundup of Clavent's Emerge Martech Virtual Summit 20:16 HKT/SGT

中国生物科技服务（8037.HK）与中国疾控中心病毒病研究所合作开发新一代新冠病毒基因工程重组疫苗 20:04 HKT/SGT

中國生物科技服務（8037.HK）與中國疾控中心病毒病研究所合作開發新一代新冠病毒基因工程重組疫苗 20:02 HKT/SGT

本识顾问推出GRI可持续发展专业认证课程 18:04 HKT/SGT

本識顧問推出GRI可持續發展專業認證課程 18:02 HKT/SGT

Alaya Consulting Offers Sustainability Certification Program by GRI 18:00 HKT/SGT

Mitsubishi Power Completes Renovation of Generating Facilities at Otake Geothermal Power Station 17:56 HKT/SGT

三菱電機、鉄道車両向け「故障予兆検知システム」を開発 16:00 HKT/SGT

DENSO Developed Factory-IoT Platform to Link 130 Factories 15:42 HKT/SGT

Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. 15:25 HKT/SGT

デンソー、世界130の工場をIoTでつなぐFactory-IoTプラットフォームを開発 15:00 HKT/SGT

田中貴金屬：以液體釕前驅物實現世界最高水準的蒸氣壓値開發CVD與ALD用前驅物「TRuST」 13:00 HKT/SGT

田中贵金属：作为液态钌前驱物实现了世界级行业标准蒸汽压力数值开发了CVD/ALD用前驱物“TRuST” 13:00 HKT/SGT

Hitachi Automotive Systems Stereo Camera with Nighttime Pedestrian Detection Adopted by Suzuki for their "Spacia" Series with Enhanced Safety Devices 10:51 HKT/SGT

NEC、スイスの大手金融ソフトウェア企業Avaloq社を傘下におくWP/AV CH Holdings I社の株式取得(子会社化)に関するお知らせ 10:00 HKT/SGT

다나까 귀금속 공업：액체 루테늄 전구체로 세계 최고 수준의 증기압치를 실현 CVD・ALD용 전구체 ‘TRuST’를 개발 10:00 HKT/SGT

富士通、全社DXプロジェクト「フジトラ」が本格始動 09:40 HKT/SGT

中國生物科技服務（8037.HK）獲中國疾控中心轉讓新冠病毒基因工程重組疫苗技術 09:30 HKT/SGT

Fujitsu Embarks on Full-Scale Launch of Ambitious DX Project "Fujitra" for Company-Wide Transformation 09:11 HKT/SGT

NEC Acquires a Leading Swiss Financial Software Company, Avaloq 08:00 HKT/SGT

コリアーズ・インターナショナル、日本代表に小笠原行洋が就任 06:00 HKT/SGT

ACN Search:

Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575